Becher B, Blain M, Giacomini P S, Antel J P
Montreal Neurological Institute, Department of Neurology and Neurosurgery, McGill University, Quebec, Canada.
J Immunol. 1999 Jan 15;162(2):684-8.
Th1-polarized CD4+ T cells are considered central to the development of a number of target-directed autoimmune disorders including multiple sclerosis. The APC-derived cytokine IL-12 is a potent inducer of Th1 polarization in T cells. Inhibition of IL-12 in vivo blocks the development of experimental allergic encephalomyelitis, the animal model for multiple sclerosis. Based on previous work that suggests that the production of IL-12 by activated human central nervous system-derived microglia is regulated by autocrine TNF-alpha, we wanted to determine whether inhibition of TNF could induce a reduction of Th1 responses by its impact on systemic APCs. We found that soluble TNFR p75-IgG fusion protein (TNFR:Fc) inhibited production of IFN-gamma by allo-Ag-activated blood-derived human CD4 T cells. We documented reduced IL-12 p70 production by APCs in the MLR. By adding back recombinant IL-12, we could rescue IFN-gamma production, indicating that TNFR:Fc acts on APC-derived IL-12. Consistent with an inhibition of the Th1 polarization, we found a decreased expression of IL-12R-beta2 subunit on the T cells. Furthermore, the capacity of T cells to secrete IFN-gamma upon restimulation when previously treated with TNFR:Fc is impaired, whereas IL-2 secretion was not altered. Our results define a TNF-dependent cytokine network that favors development of Th1 immune responses.
Th1极化的CD4+ T细胞被认为是包括多发性硬化症在内的多种靶向自身免疫性疾病发展的核心。抗原呈递细胞(APC)衍生的细胞因子IL-12是T细胞中Th1极化的有效诱导剂。体内抑制IL-12可阻断实验性变应性脑脊髓炎(多发性硬化症的动物模型)的发展。基于先前的研究表明,活化的人中枢神经系统来源的小胶质细胞产生的IL-12受自分泌TNF-α调节,我们想确定抑制TNF是否会通过影响全身APC而导致Th1反应降低。我们发现可溶性TNFR p75-IgG融合蛋白(TNFR:Fc)抑制同种异体抗原激活的血液来源的人CD4 T细胞产生IFN-γ。我们记录到混合淋巴细胞反应(MLR)中APC产生的IL-12 p70减少。通过添加重组IL-12,我们可以挽救IFN-γ的产生,表明TNFR:Fc作用于APC衍生的IL-12。与Th1极化的抑制一致,我们发现T细胞上IL-12R-β2亚基的表达降低。此外,先前用TNFR:Fc处理的T细胞在再次刺激时分泌IFN-γ的能力受损,而IL-2分泌未改变。我们的结果定义了一个依赖TNF的细胞因子网络,该网络有利于Th1免疫反应的发展。